Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Chimeric Therapeutics Ltd. ( (AU:CHM) ) has shared an announcement.
Chimeric Therapeutics has successfully raised $6.6 million through a two-tranche placement, supported by institutional and professional investors, to advance its clinical trial pipeline. The funds will primarily support the progression of the CHM CDH17 CAR-T and CORE-NK clinical trials, enhancing the company’s ability to reach key clinical milestones and potentially strengthen its market position.
More about Chimeric Therapeutics Ltd.
Chimeric Therapeutics is a clinical-stage cell therapy company dedicated to advancing innovative cell therapies for cancer patients. The company focuses on the discovery, development, and commercialization of pioneering cell therapies, including autologous CAR-T and allogeneic NK cell therapies, with a diversified portfolio targeting various oncology disease areas.
Technical Sentiment Signal: Sell
Current Market Cap: A$14.81M
Learn more about CHM stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue